Literature DB >> 28978216

Economic impact of and treatment options for type 2 diabetes.

Jan D Hirsch, Candis M Morello.   

Abstract

Diabetes and its various comorbidities are responsible for a substantial societal financial burden. Healthcare and managed care providers must take responsibility for and address the high healthcare costs attributed to diabetes care. They can work together to improve diabetes-related patient care and reduce costs. Newer therapeutic agents and those used as combination therapy may decrease direct costs by improving glycemic control and preventing negative outcomes associated with diabetes comorbidities. Additional diabetes education, increased time to review medication adherence and diabetes monitoring, and having affordable care are all necessary to improve the care of individuals with diabetes.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28978216

Source DB:  PubMed          Journal:  Am J Manag Care        ISSN: 1088-0224            Impact factor:   2.229


  3 in total

1.  Health Care Costs Associated With Macrovascular, Microvascular, and Metabolic Complications of Type 2 Diabetes Across Time: Estimates From a Population-Based Cohort of More Than 0.8 Million Individuals With Up to 15 Years of Follow-up.

Authors:  Hsuan-Ying Chen; Shihchen Kuo; Pei-Fang Su; Jin-Shang Wu; Huang-Tz Ou
Journal:  Diabetes Care       Date:  2020-05-22       Impact factor: 19.112

2.  Developing a User-Centered Digital Clinical Decision Support App for Evidence-Based Medication Recommendations for Type 2 Diabetes Mellitus: Prototype User Testing and Validation Study.

Authors:  Kevin Larsen; Bilikis Akindele; Henry Head; Rick Evans; Purvi Mehta; Quinn Hlatky; Brendan Krause; Sydney Chen; Dominic King
Journal:  JMIR Hum Factors       Date:  2022-01-18

3.  Differences in U.S. Rural-Urban Trends in Diabetes ABCS, 1999-2018.

Authors:  Carla I Mercado; Kai McKeever Bullard; Edward W Gregg; Mohammed K Ali; Sharon H Saydah; Giuseppina Imperatore
Journal:  Diabetes Care       Date:  2021-06-14       Impact factor: 17.152

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.